A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment.
The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months.
Following one year of treatment patients could proceed into the study extension.
Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) were switched to the other treatment arm at month 13.
Inclusion criteria:
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Los Angeles, California 90095, United States
Stanford, California 94304, United States
Baltimore, Maryland 21205, United States
Ann Arbor, Michigan 48109-0944, United States
New York, New York 10032, United States
Portland, Oregon 97201, United States
Dallas, Texas 75390, United States
Houston, Texas 77030-4009, United States
CABA, Buenos Aires C1405BCH, Argentina
Capital Federal, Buenos Aires 1425EKP, Argentina
Bogota, Cundinamarca 111411, Colombia